← FDA DRUG APPROVALS

FDA ANDA · ANDA088656

QUIBRON-T

Sponsor: MONARCH PHARMS

APPLICATION
ANDA088656
TYPE
ANDA
ORIGINAL APPROVAL
1985-08-22
LATEST ACTION
1997-06-23
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

QUIBRON-TDiscontinued
THEOPHYLLINE 300MG · TABLET · ORAL

Approval history

1997-06-23Labeling · Supplement 9AP
1997-02-07Labeling · Supplement 8AP
1996-07-22Manufacturing (CMC) · Supplement 7AP
1991-04-09Labeling · Supplement 6AP
1989-05-10Labeling · Supplement 3AP
1989-02-23Manufacturing (CMC) · Supplement 4AP
1989-02-23Manufacturing (CMC) · Supplement 5AP
1988-04-05Manufacturing (CMC) · Supplement 2AP
1985-11-26Manufacturing (CMC) · Supplement 1AP
1985-08-22OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →